a first-in-class mitochondria-targeted therapeutic in development for individuals with Barth syndrome. The new PDUFA target action date is April 29, 2025. Stealth BioTherapeutics Logo (PRNewsFoto ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback